Literature DB >> 28606646

Current Use and Trends in Hematopoietic Cell Transplantation in the United States.

Anita D'Souza1, Stephanie Lee2, Xiaochun Zhu3, Marcelo Pasquini4.   

Abstract

Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve. We report on general overall survival by indication, by disease status at transplantation, and by transplant type. This report provides a current perspective on transplantation activity in the United States with a focus on recent trends in alternative donors and contemporary transplantation practices.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HCT activity; Trends; US

Mesh:

Substances:

Year:  2017        PMID: 28606646      PMCID: PMC5565685          DOI: 10.1016/j.bbmt.2017.05.035

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  2 in total

1.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

2.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

  2 in total
  64 in total

1.  Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors.

Authors:  Brian Kornblit; Barry E Storer; Niels S Andersen; Michael B Maris; Thomas R Chauncey; Effie W Petersdorf; Ann E Woolfrey; Mary E D Flowers; Rainer Storb; David G Maloney; Brenda M Sandmaier
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

Review 2.  Advances in Treatment of Cardiac Amyloid.

Authors:  Cherie N Dahm; R Frank Cornell; Daniel J Lenihan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

3.  Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.

Authors:  Mehdi Hamadani; Manoj Khanal; Kwang W Ahn; Carlos Litovich; Victor A Chow; Alireza Eghtedar; Reem Karmali; Allison Winter; Timothy S Fenske; Craig Sauter; Mohamed A Kharfan-Dabaja; Farrukh T Awan
Journal:  Biol Blood Marrow Transplant       Date:  2020-03-09       Impact factor: 5.742

4.  Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors.

Authors:  Lori Wiener; Jennifer A Hoag; Wendy Pelletier; Nirali N Shah; Bronwen E Shaw; Michael A Pulsipher; Jessica Bruce; Peter Bader; Andre M Willasch; Arnaud Dalissier; Gregory Guilcher; Chloe Anthias; Dennis L Confer; Jennifer A Sees; Brent Logan; Galen E Switzer
Journal:  Bone Marrow Transplant       Date:  2019-04-10       Impact factor: 5.483

5.  Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

Authors:  Jennifer M Knight; J Douglas Rizzo; Parameswaran Hari; Marcelo C Pasquini; Karen E Giles; Anita D'Souza; Brent R Logan; Mehdi Hamadani; Saurabh Chhabra; Binod Dhakal; Nirav Shah; Deepika Sriram; Mary M Horowitz; Steve W Cole
Journal:  Blood Adv       Date:  2020-02-11

6.  Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation.

Authors:  Anita D'Souza; Heather Millard; Jennifer Knight; Ruta Brazauskas; Stephanie J Lee; Kathryn E Flynn; J Douglas Rizzo; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-03-07       Impact factor: 5.483

7.  Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell.

Authors:  Jonathan Hoggatt; Pratibha Singh; Tiffany A Tate; Bin-Kuan Chou; Shruti R Datari; Seiji Fukuda; Liqiong Liu; Peter V Kharchenko; Amir Schajnovitz; Ninib Baryawno; Francois E Mercier; Joseph Boyer; Jason Gardner; Dwight M Morrow; David T Scadden; Louis M Pelus
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

Review 8.  B cells in chronic graft-versus-host disease.

Authors:  William McManigle; Ayman Youssef; Stefanie Sarantopoulos
Journal:  Hum Immunol       Date:  2019-03-05       Impact factor: 2.850

9.  Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.

Authors:  Benjamin A Derman; Keriann Kordas; Jean Ridgeway; Selina Chow; William Dale; Sang Mee Lee; Elingel Aguada; Andrzej J Jakubowiak; Jagoda Jasielec; Justin Kline; Satyajit Kosuri; Richard A Larson; Hongtao Liu; Mylove Mortel; Olatoyosi Odenike; Jennifer Pisano; Peter Riedell; Wendy Stock; Michael R Bishop; Andrew S Artz
Journal:  Blood Adv       Date:  2019-11-26

10.  Reduction in Mortality after Umbilical Cord Blood Transplantation in Children Over a 20-Year Period (1995-2014).

Authors:  Lisa P Spees; Paul L Martin; Joanne Kurtzberg; Andre Stokhuyzen; Lauren McGill; Vinod K Prasad; Timothy A Driscoll; Suhag H Parikh; Kristin M Page; Richard Vinesett; Christopher Severyn; Anthony D Sung; Alan D Proia; Kirsten Jenkins; Mehreen Arshad; William J Steinbach; Patrick C Seed; Matthew S Kelly
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.